MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Im, H. K.
Right arrow Articles by Vonvoigtlander, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Im, H. K.
Right arrow Articles by Vonvoigtlander, P. F.

Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma- aminobutyric acid type A receptors

HK Im, WB Im, BJ Hamilton, DB Carter and PF Vonvoigtlander

Upjohn Company, Kalamazoo, Michigan 49001.

Previous studies with cloned gamma-aminobutyric acid type A receptors expressed in human embryonic kidney cells have indicated that the alpha 1 beta 2 gamma 2 and alpha 1 gamma 2 (but not alpha 1 beta 2) subtypes have benzodiazepine sites. We found in this study that even the beta 2 gamma 2 subtype displays gamma-aminobutyric acid-induced Cl- currents that are potentiated by triazolam (a triazolobenzodiazepine). The maximal efficacy of the drug among the subtypes was highest with the alpha 1 beta 2 gamma 2 subtype, followed by the alpha 1 gamma 2 and beta 2 gamma 2 subtypes. These observations led us to compare the ability of several benzodiazepine site agonists of diverse chemical structures to potentiate Cl- currents with these subtypes. With the alpha 1 gamma 2 subtype, diazepam, alpidem, zolpidem, Cl-218872, zopiclone, U-79098 (an imidazoquinoxaline derivative), and U-90167 (a diimidazoquinazoline derivative) at 5 microM potentiated Cl- currents to essentially similar levels (slightly lower for a few ligands), compared with those with the alpha 1 beta 2 gamma 2 subtype. With the beta 2 gamma 2 subtype, the type 1 ligands zolpidem, alpidem, and Cl- 218872 showed no or very low levels of potentiation, whereas less selective ligands such as diazepam, zopiclone, U-78098, and U-90167 displayed levels of Cl- current potentiation comparable to those observed with the subtypes containing the alpha 1 and gamma 2 subunits. These data indicate that, in the presence of gamma 2, beta 2 may substitute for alpha 1 in forming the benzodiazepine site of limited sensitivity to the type 1 ligands. It appears that individual ligands for benzodiazepine sites have their own sets of interacting domains, which are distributed in alpha 1 and gamma 2, and the agonistic activity of type 1 ligands may be more dependent on the alpha 1- specific domains than is that of less selective ligands.

Volume 44, Issue 4, pp. 866-870, 10/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. K. Sullivan, R. E. Petroski, G. Verge, R. S. Gross, A. C. Foster, and D. E. Grigoriadis
Characterization of the Interaction of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic, with the GABAA Receptor
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 537 - 546.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. W. Fleck
Molecular Actions of (S)-Desmethylzopiclone (SEP-174559), an Anxiolytic Metabolite of Zopiclone
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 612 - 618.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Vicini, C. Ferguson, K. Prybylowski, J. Kralic, A. L. Morrow, and G. E. Homanics
GABAA Receptor {alpha}1 Subunit Deletion Prevents Developmental Changes of Inhibitory Synaptic Currents in Cerebellar Neurons
J. Neurosci., May 1, 2001; 21(9): 3009 - 3016.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. M. J. Dunn, M. Davies, A. L. Muntoni, and J. J. Lambert
Mutagenesis of the Rat alpha 1 Subunit of the gamma -Aminobutyric AcidA Receptor Reveals the Importance of Residue 101 in Determining the Allosteric Effects of Benzodiazepine Site Ligands
Mol. Pharmacol., October 1, 1999; 56(4): 768 - 774.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
A. J. Boileau, A. M. Kucken, A. R. Evers, and C. Czajkowski
Molecular Dissection of Benzodiazepine Binding and Allosteric Coupling Using Chimeric gamma -Aminobutyric AcidA Receptor Subunits
Mol. Pharmacol., February 1, 1998; 53(2): 295 - 303.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. Amin, A. Brooks-Kayal, and D. S. Weiss
Two Tyrosine Residues on the alpha  Subunit Are Crucial for Benzodiazepine Binding and Allosteric Modulation of gamma -Aminobutyric AcidA Receptors
Mol. Pharmacol., May 1, 1997; 51(5): 833 - 841.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
W. B. Im, J. F. Pregenzer, J. A. Binder, G. H. Dillon, and G. L. Alberts
Chloride Channel Expression with the Tandem Construct of alpha6-beta2 GABA(A) Receptor Subunit Requires a Monomeric Subunit of alpha6 or [IMAGE]2
J. Biol. Chem., November 3, 1995; 270(44): 26063 - 26066.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics